Scotiabank initiated coverage of Vertex Pharmaceuticals (VRTX) with an Outperform rating and $495 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Buy These 3 Stocks Now, Say Five-Star Analysts – November 11, 2025
- Vertex Pharmaceuticals: Hold Rating Amid High Valuation and Uncertain Growth Prospects Beyond Cystic Fibrosis
- Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development
- Vertex Pharmaceuticals’ Promising Renal Franchise Developments Justify Buy Rating
- Cautious Optimism: Hold Rating on Vertex Pharmaceuticals Amid Promising Clinical Trial Data